MCID: NPH010
MIFTS: 42

Nephrosclerosis malady

Categories: Rare diseases, Cardiovascular diseases, Nephrological diseases

Aliases & Classifications for Nephrosclerosis

About this section

Aliases & Descriptions for Nephrosclerosis:

Name: Nephrosclerosis 11 48 27 50 39 13 68
 
Renal Sclerosis 11

Classifications:



External Ids:

Disease Ontology11 DOID:11664
ICD1030 I12, N26.9
ICD9CM32 587
MeSH39 D009400

Summaries for Nephrosclerosis

About this section
MalaCards based summary: Nephrosclerosis, also known as renal sclerosis, is related to fatal infantile hypertrophic cardiomyopathy due to mitochondrial complex i deficiency and ovarian cancer. An important gene associated with Nephrosclerosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways are A-beta Pathways: Uptake and Degradation and Renin secretion. Affiliated tissues include kidney, pituitary and heart, and related mouse phenotypes are cardiovascular system and growth/size/body region.

Related Diseases for Nephrosclerosis

About this section

Diseases related to Nephrosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 121)
idRelated DiseaseScoreTop Affiliating Genes
1fatal infantile hypertrophic cardiomyopathy due to mitochondrial complex i deficiency10.6ACE, TGFB1
2ovarian cancer10.6ACE, AGTR1
3casr-related disorders10.6ACE, AGTR1
4congenital methemoglobinemia10.5AGTR1, TGFB1
5chylocele of tunica vaginalis10.5ACE, AGTR1
6burns10.5ACE, TGFB1
7podder-tolmie syndrome10.4ADRB1, AGTR1
8vibrio vulnificus infection10.4CCL2, TGFB1
9fibula aplasia complex brachydactyly10.4ACE, AGTR1, TGFB1
10post-infectious myocarditis10.4ACE, AGTR1, TGFB1
11suppurative uveitis10.4CCL2, SYNPO
12kidney hypertrophy10.4ACE, AGTR1, TGFB1
13lymphogranuloma venereum10.4CTGF, TGFB1
14renal dysplasia, bilateral10.3CTGF, SYNPO
15hypohidrosis10.3CTGF, TGFB1
16twin-to-twin transfusion syndrome10.3CCL2, TGFB1
17aortic valves stenosis of the child10.3ACE, ADRB1, AGTR1
18broad ligament malignant neoplasm10.3ACE, ADRB1, AGTR1
19acromicric dysplasia10.3CTGF, TGFB1
20renal tubular dysgenesis10.3ACE, AGTR1
21craniosynostosis10.3ACE, ADRB1, AGTR1
22respiratory syncytial virus infectious disease10.3ACE, MTHFR
23sinusitis10.3ACE, CCL2, TGFB1
24laryngeal tuberculosis10.2ACE, CCL2, TGFB1
25basaloid squamous cell carcinoma10.2ACE, CCL2, TGFB1
26fundus dystrophy10.2ACE, CCL2, TGFB1
27vitreous abscess10.2CTGF, TGFB1
28antiphospholipid syndrome10.2ACE, AGTR1, NR3C2
29benign hypertensive renal disease10.2ACE, AGTR1, NR3C2
30islet cell tumor10.2ACE, MTHFR
31collecting duct carcinoma10.2ACE, AGTR1, NR3C2
32hepatocellular adenoma10.2ACE, MTHFR
33salt and pepper syndrome10.2CTGF, TGFB1
34citrullinemia, adult-onset type ii10.1ACE, AGTR1, CTGF
35temporomandibular ankylosis10.1ACE, CTGF, TGFB1
36echinococcosis10.1CTGF, TGFB1
37oesophagostomiasis10.1ACE, CCL2
38aphthous stomatitis10.1ACE, ADRB1, NR3C2
39joint disorders10.1ACE, AGTR1, MTHFR
40histoplasmosis10.1CCL2, MTHFR
41anti-basement membrane glomerulonephritis10.1CCL2, CTGF
42actinomycosis10.1CTGF, TGFB1
43alpha-2-plasmin inhibitor deficiency10.1ACE, AGTR1, MTHFR
44littre gland carcinoma10.0ACE, AGTR1, MTHFR
45benign struma ovarii10.0CCL2, CTGF, TGFB1
46prediabetes syndrome10.0CCL2, MTHFR
47gemistocytic astrocytoma10.0ACE, AGTR1, CCL2, TGFB1
48nonspecific interstitial pneumonia10.0CCL2, CTGF, TGFB1
49exudative vitreoretinopathy 110.0CCL2, CTGF, TGFB1
50nephropathy familial with hyperuricemia10.0CTGF, TGFB1

Comorbidity relations with Nephrosclerosis via Phenotypic Disease Network (PDN):


Acute Kidney FailureChronic Kidney Failure
Deficiency AnemiaHeart Disease
Hypertension, EssentialIschemic Heart Disease
Acute CystitisHydronephrosis
NephrolithiasisPrimary Hyperoxaluria

Graphical network of the top 20 diseases related to Nephrosclerosis:



Diseases related to nephrosclerosis

Symptoms & Phenotypes for Nephrosclerosis

About this section

MGI Mouse Phenotypes related to Nephrosclerosis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053858.2ACE, ADRB1, AGTR1, BMP5, CTGF, NPHS2
2MP:00053787.6ACE, ADRB1, AGTR1, BMP5, CTGF, MTHFR
3MP:00053677.2ACE, AGTR1, BMP5, NPHS1, NPHS2, NR3C2
4MP:00053767.1ACE, ADRB1, AGTR1, CTGF, MTHFR, NPHS1
5MP:00107686.7ACE, ADRB1, AGTR1, BMP5, CTGF, MTHFR

Drugs & Therapeutics for Nephrosclerosis

About this section

Drugs for Nephrosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Valsartanapproved, investigationalPhase 4291137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
2Antihypertensive AgentsPhase 4, Phase 2, Phase 34095
3Angiotensin II Type 1 Receptor BlockersPhase 41078
4
Angiotensin IIPhase 4116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
5Angiotensin Receptor AntagonistsPhase 41173
6AngiotensinogenPhase 41161
7
EpoprostenolapprovedPhase 2, Phase 35361849-14-7, 35121-78-95280427, 5282411
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
Bio2_000216
Bio2_000696
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
CID6434194
CID6450541
 
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KB-IV-24
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PG-I2
PGI(sub 2)
PGI2
PGX
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
Prostaglandin I2
Prostaglandin X
Prostaglandin x
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
epoprostenol
prostacyclin
prostaglandin I2
8BeraprostinvestigationalPhase 2, Phase 31588430-50-6
9Vasodilator AgentsPhase 2, Phase 33438
10Platelet Aggregation InhibitorsPhase 2, Phase 32419
11TezosentanPhase 2, Phase 365

Interventional clinical trials:

idNameStatusNCT IDPhase
1Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseTerminatedNCT01129557Phase 4
2TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)CompletedNCT01090037Phase 2, Phase 3
3TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)CompletedNCT02480751Phase 2
4Renal NCE-MRI in Healthy VolunteersCompletedNCT02618460

Search NIH Clinical Center for Nephrosclerosis


Cochrane evidence based reviews: nephrosclerosis

Genetic Tests for Nephrosclerosis

About this section

Genetic tests related to Nephrosclerosis:

id Genetic test Affiliating Genes
1 Nephrosclerosis27

Anatomical Context for Nephrosclerosis

About this section

MalaCards organs/tissues related to Nephrosclerosis:

36
Kidney, Pituitary, Heart, Pancreas, Bone, Smooth muscle, Endothelial

Publications for Nephrosclerosis

About this section

Articles related to Nephrosclerosis:

(show top 50)    (show all 268)
idTitleAuthorsYear
1
Curcumin ameliorates nephrosclerosis via suppression of histone acetylation independent of hypertension. (27190365)
2016
2
Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis. (26809068)
2016
3
Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. (26857648)
2016
4
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. (27784849)
2016
5
Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. (27066888)
2016
6
Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. (26839894)
2016
7
Glomerular Density in Biopsy-Proven Hypertensive Nephrosclerosis. (25631380)
2015
8
The Renal Protective Effect of Jiangya Tongluo Formula, through Regulation of Adrenomedullin and Angiotensin II, in Rats with Hypertensive Nephrosclerosis. (26557147)
2015
9
Nephrosclerosis: A Term in Quest of a Disease. (25871843)
2015
10
Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years' experience in a single, kidney disease center. (25838316)
2015
11
Malignant nephrosclerosis in a patient with familial Mediterranean fever. (26466703)
2015
12
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. (24958497)
2014
13
A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. (25233856)
2014
14
Nephrosclerosis: update on a centenarian. (25488894)
2014
15
Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis. (23151750)
2013
16
Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. (23832327)
2013
17
Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. (24327566)
2013
18
Endothelial Sirtuin 1 Deficiency Perpetrates Nephrosclerosis through Downregulation of Matrix Metalloproteinase-14: Relevance to Fibrosis of Vascular Senescence. (24136919)
2013
19
Castleman's disease accompanied by hypolipidemic cerebral hemorrhage and nephrosclerosis. (23857095)
2013
20
Hypertensive nephrosclerosis: not enough of a good thing? (23283991)
2013
21
Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis. (24102027)
2013
22
Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. (23902971)
2013
23
Subclinical nephrosclerosis is linked to left ventricular hypertrophy independent of classical atherogenic factors. (24305517)
2013
24
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. (23135868)
2013
25
Need for education on the differential diagnosis between chronic glomerulonephritis and nephrosclerosis, and treatment of both conditions to reduce the number of patients requiring hemodialysis in Wakayama. (22821095)
2012
26
Association of hypoalbuminemia with severe anemia in patients with diabetic nephrosclerosis. (22236281)
2012
27
Arteriolar vascular smooth muscle cell differentiation in benign nephrosclerosis. (22319217)
2012
28
Hypertensive nephrosclerosis in Kenya. (22179094)
2011
29
Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging? (21832860)
2011
30
Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. (21346373)
2011
31
Involvement of connective tissue growth factor in human and experimental hypertensive nephrosclerosis. (20689330)
2011
32
The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis. (21319131)
2011
33
Nephrosclerosis and carotid atherosclerosis: lessons from kidney donor histology. (21777346)
2011
34
ADAMTS13--marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. (20923926)
2011
35
Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. (21080950)
2010
36
Human nephrosclerosis triggers a hypoxia-related glomerulopathy. (20019191)
2010
37
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. (20651163)
2010
38
Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. (20801567)
2010
39
The association between age and nephrosclerosis on renal biopsy among healthy adults. (20439574)
2010
40
Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. (19910931)
2010
41
Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. (20484896)
2010
42
Podocyte loss in human hypertensive nephrosclerosis. (19131934)
2009
43
Renal dysplasia and nephrosclerosis in calves. (19933543)
2009
44
Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. (19745105)
2009
45
Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]. (19799194)
2009
46
Hypertensive nephrosclerosis. (18408477)
2008
47
(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. (18212268)
2008
48
Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. (18698220)
2008
49
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). (17998773)
2007
50
Functional polymorphism of the myeloperoxidase gene in hypertensive nephrosclerosis dialysis patients. (18344624)
2007

Variations for Nephrosclerosis

About this section

Expression for genes affiliated with Nephrosclerosis

About this section
Search GEO for disease gene expression data for Nephrosclerosis.

Pathways for genes affiliated with Nephrosclerosis

About this section

GO Terms for genes affiliated with Nephrosclerosis

About this section

Cellular components related to Nephrosclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1slit diaphragmGO:00360579.2NPHS1, NPHS2

Biological processes related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1mononuclear cell proliferationGO:003294310.6ACE, TGFB1
2regulation of systemic arterial blood pressure by renin-angiotensinGO:000308110.5ACE, AGTR1
3regulation of vasoconstrictionGO:001922910.5ACE, AGTR1
4regulation of vasodilationGO:004231210.5ACE, AGTR1
5positive regulation of cellular protein metabolic processGO:003227010.5AGTR1, TGFB1
6cellular response to dexamethasone stimulusGO:007154910.4CCL2, TGFB1
7lipopolysaccharide-mediated signaling pathwayGO:003166310.4CCL2, TGFB1
8protein kinase B signalingGO:004349110.4CCL2, TGFB1
9negative regulation of gene expressionGO:001062910.0ACE, CTGF, TGFB1
10agingGO:00075689.9CCL2, CTGF, TGFB1
11positive regulation of collagen biosynthetic processGO:00329679.9CCL2, CTGF, TGFB1
12response to hypoxiaGO:00016669.6CCL2, MTHFR, TGFB1
13response to amino acidGO:00432009.5CCL2, CTGF, MTHFR
14response to woundingGO:00096119.2CCL2, CTGF, TGFB1

Molecular functions related to Nephrosclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1bradykinin receptor bindingGO:003171110.6ACE, AGTR1
2cytokine activityGO:000512510.0BMP5, CCL2, TGFB1
3growth factor activityGO:00080839.3BMP5, CTGF, TGFB1

Sources for Nephrosclerosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet